Page 4 - Patient Support Program News Today

BeiGene Announces Health Canada Approval for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Marginal Zone Lymphoma - read this article along with other careers information, tips and advice on BioSpace

/PRNewswire/ -- Taiwan-based digital health startup Health2Sync makes further inroads in personalized chronic disease management with an expanded coverage of...

Learn more about the importance of N95 and K95 masks for better COVID-19 protection if you’re immunocompromised or high risk.

04.12.2021 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, for the adjuvant treatment of adult and pediatric (12 years and ...

This Is the First Anti-PD-1 Combination Approved as First-Line Treatment for These Patients Merck known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent or metastatic cervical cancer whose ...

May 18, 2021 Manage the Patient Support Program (PSP) for Copaxone Support (Helpline and email address) for new and existing patients, Solus V2 Helpline, assist upon request with other patient support programs or projects to be allocated as and when required by line manager. Start new patients on Copaxone Ensure that new patients understand the product and injection techniques in order to solve their queries with regards to the same Plan quarterly calls / visits to existing Copaxone patients ...

Operator Good day and welcome to the alboreto pharma first quarter 2021 earnings conference call. [Operator Instructions] At this time, I would like to turn the conference over to Mr. Paul. Please go ahead, sir. Paul S. Bavier -- Interim President, General Counsel And Secretary Thank you, operator and good morning everyone. Thank you for joining todays call. This morning, Alberto issued a press release highlighting its recent business accomplishments and reporting its financial results for the...

Published: Apr 23, 2021   First and only CD19-targeted antibody drug conjugate (ADC) as a single-agent treatment for adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) ZYNLONTA addresses an unmet need across a broad population of third-line (3L)+ r/r patients, including patients with DLBCL not otherwise specified, DLBCL arising from low grade lymphoma and high-grade B-cell lymphoma ZYNLONTA demonstrated 48.3% overall response rate, 24.1% complete respon...

(0) First and only CD19-targeted antibody drug conjugate (ADC) as a single-agent treatment for adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) ZYNLONTA addresses an unmet need across a broad population of third-line (3L)+ r/r patients, including patients with DLBCL not otherwise specified, DLBCL arising from low grade lymphoma and high-grade B-cell lymphoma ZYNLONTA demonstrated 48.3% overall response rate, 24.1% complete response rate and durable respons...

Published: Apr 08, 2021 Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults AJOVY® now offers patients greater flexibility with two dosing options available in both an autoinjector and a prefilled syringe AJOVY® is the first and only subcutaneous anti-CGRP treatment with both quarterly (every three months) and monthly dosing options using either the autoinjector or prefilled syringe for the preventive treatment of migraine in adults. AJOVY...